Project Grant R21DA064011
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $294K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The U.S. Department of Health and Human Services' National Institutes of Health (NIH) awarded a $189,672 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Davidson College in North Carolina. The grant, awarded on August 15, 2025, supports a study titled "Fentanyl and Xylazine Interactions: Toxicity Produced by 'Tranq-Dope'." The project aims to quantify the interactions between fentanyl (a mu opioid receptor agonist) and xylazine (an alpha 2 adrenergic...
- This Project Grant award, valued at $506,000.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Scripps Research Institute to develop monoclonal antibodies that can block the mechanism of action and adverse effects of the drug xylazine. Xylazine has emerged as an adulterant in illicit drug mixtures, contributing to overdose deaths, and this research aims to create novel therapeutic...
- This federal Project Grant award of $233,250 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to evaluate the prevalence of the illicit drug adulterant xylazine and investigate the etiology of xylazine-related invasive infections. The key products/services to be delivered through this 2-year project include: Active surveillance of the local illicit drug supply in St. Louis, Missouri, using mass spectrometry and microbiologic...
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- This $197,024 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports two multi-methods studies to characterize the impact of the veterinary tranquilizer xylazine on people who use drugs (PWUD) in North Carolina and Maine. The first study in North Carolina aims to describe PWUD's perceptions and experiences with xylazine and related complications, such as overdoses and skin ulcers, through surveys...
- This federal Project Grant award of $272,395.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop methods for targeting the G9A and GLP enzymes, which are involved in the development of addictive behaviors to stimulants and opioids. The research aims to better understand the molecular functions of G9A and GLP in the addiction process and explore therapeutic approaches that do not rely on catalytic site...
- The Project Grant award of $231,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the University of Rochester to determine if the drug xylazine and its metabolites act as agonists or positive allosteric modulators at the mu and kappa opioid receptors. Additional studies will investigate whether xylazine and its metabolites are agonists, antagonists, or inverse agonists at the sigma 1 and sigma 2 receptors....
- This $387,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research by Mercer University to investigate the molecular pharmacology of the drug xylazine and its effects on adrenoceptors. The research aims to assess xylazine's binding affinity and functional profiles at different adrenoceptor subtypes expressed in vascular smooth muscle cells, as well as directly test the hypothesis that...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to evaluate the effects of the drug xylazine on methamphetamine-induced behaviors in rats. The $237,750 award to Temple University, a prominent public research university, aims to define the unique behavioral and molecular consequences of exposing rats to both methamphetamine and xylazine. The studies will test the...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct research on the effects of xylazine and opioids on prefrontal cortex inhibitory transmission. The research aims to understand xylazine's cell signaling profiles and interactions with opioids at the circuit level, as xylazine is becoming highly prevalent in illicit opioid supplies and poses an...